Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 1, 1998, Pages 239-247

  Ågmo, Anders ^a   Belzung, Catherine ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Ambulatory activity; Dopamine; GABA; Mouse; Neophobia

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINO 5 HEXYNOIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; AMPHETAMINE; BICUCULLINE; DOPAMINE; PROGABIDE;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG POTENTIATION; MALE; MOTOR ACTIVITY; MOUSE; NEOPHOBIA; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REARING;

AMPHETAMINE; ANIMALS; CHI-SQUARE DISTRIBUTION; DOPAMINE; DOPAMINE AGENTS; EXPLORATORY BEHAVIOR; GABA AGONISTS; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; PHOBIC DISORDERS;

ANIMALIA;

EID: 0031973458     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00338-9     Document Type: Article

References (64)

1. Ågmo A., Giordano M. The locomotor-reducing effects of GABAergic drugs do not depend on the GABA-A receptor. Psychopharmacology (Berlin). 87:1985;51-54.
2. Ågmo A., Tarasco C. Interactions between naloxone and GABA in the control of locomotor activity in the rat. J. Neural Transm. 61:1985;137-149.
3. Ågmo A., Belzung C., Giordano M. Interaction between dopamine and GABA in the control of ambulatory activity. J. Neural Transm. 103:1996;925-934.
4. Ågmo A., Pruneda R., Guzmán M., Gutiérrez M. GABAergic drugs and conflict behavior in the rat. Lack of similarities with the actions of benzodiazepines Naunyn Schmiedebergs Arch. Pharmacol. 344:1991;314-322.
5. B agonist progabide are differentially blocked by GABA receptor antagonists. Psychopharmacology (Berlin). 129:1997;27-34.
6. Ahlenius S., Carlsson A., Engel J. Antagonism by baclophen of the d-amphetamine-induced disruption of a successive discrimination in the rat. J. Neural Transm. 36:1975;327-333.
7. Andén N. E., Lindgren S., Magnusson Å. Regional differences in the changes in rat brain GABA consentrations post mortem and following inhibition of synthesis and metabolism. Pharmacol. Toxicol. 60:1987;393-396.
8. Arnt J., Christensen A. V., Scheel-Krüger J. Benzodiazepines potentiate GABA-dopamine stereotyped dependent gnawing in mice. J. Pharm. Pharmacol. 31:1979;56-58.
9. Belzung C., Misslin R., Vogel E., Dodd R. H., Chapoutier G. Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice sitation. Pharmacol. Biochem. Behav. 28:1987;29-33.
10. Belzung C., Misslin R., Vogel E. The benzodiazepine receptor inverse agonists beta-CCM and RO 15-305 both reverse the anxiolytic effects of ethanol in mice. Life Sci. 42:1988;1765-1772.
11. Belzung C., Misslin R., Vogel E. Anxiogenic effects of a benzodiazepine receptor partial inverse agonist, RO 19-4603, in a light/dark choice situation. Pharmacol. Biochem. Behav. 36:1990;593-596.
12. A receptors. Neuropharmacology. 21:1982;391-395.
13. Christensen A. V., Arnt J., Scheel-Krüger J. GABA-dopamine/neuroleptic interaction after systemic administration. Brain Res. Bull. 5(Suppl. 2):1980;885-890.
14. Cott J., Engel J. Suppression by GABAergic drugs of the locomotor stimulation induced by morphine, amphetamine, and apomorphine. Evidence for both pre- and postsynaptic inhibition of catecholamine systems J. Neural Transm. 40:1977;253-268.
15. Di Scala G., Martin-Iverson M. T., Phillips A. G., Fibiger H. C. The effects of progabide (SL76002) on locomotor activity and conditioned place preference induced by d-amphetamine. Eur. J. Pharmacol. 107:1985;271-274.
16. D'Mello G., Stolerman I. P. Interaction of cocaine with chlordiazepoxide assessed by motor activity in mice. Br. J. Pharmacol. 59:1977;141-145.
17. File S. E., Hyde J. R. G. A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol. Biochem. Behav. 11:1979;65-69.
18. File S. E., Wardill A. G. Validity of head-dipping as a measure of exploration in a modified holeboard. Psychopharmacologia. 44:1975;53-59.
19. Gardner C. R., Piper D. C. Effects of agents which enhance GABA-mediated neurotransmission on licking conflict in rats and exploration in mice. Eur. J. Pharmacol. 83:1982;25-33.
20. Geller I., Seifter J. The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia. 1:1960;482-492.
21. Gray J. A., Quintero S., Mellanby J., Buckland C., Fillenz M., Frang S. C. Some biochemical, behavioural, and electrophysiological tests of the GABA hypothesis of anti-anxiety drug action. Bowery N. Actions and interactions of GABA and benzodiazepines. 1984;239-262 Raven Press, New York.
22. Griebel G., Belzung C., Misslin R., Vogel E. The free-exploratory paradigm. An effective method for measuring neophobic behavior in mice and testing potential neophobia-reducing drugs Behav. Pharmacol. 4:1993;637-644.
23. Johnston G. A. R. GABAC receptors. Relatively simple transmitter-gated ion channels? Trends Pharmacol. Sci. 17:1996;319-323.
24. Kabuto H., Yokoi I., Iwaya K., Mori A. Monoamine release in the rat striatum is induced by d-guanidinovaleric acid and inhibited by GABA agonists. Life Sci. 56:1995;1741-1748.
25. Karler R., Calder L. D., Thai L. H., Bedingfeld J. B. The dopaminergic, glutamatergic, GABAergic basis for the action of amphetamine and cocaine. Brain Res. 671:1995;100-104.
26. Klitenick M. A., DeWitte P., Kalivas P. W. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA. An in vivo microdialysis study J. Neurosci. 12:1992;2623-2632.
27. Kumar R. Exploration and latent learning. Differential effects of dexamphetamine on components of exploratory behavior in rats Psychopharmacologia. 16:1969;54-72.
28. Le Moal M., Simon H. Mesocorticolimbic network. Functional and regulatory roles Physiol. Rev. 71:1991;155-234.
29. Lloyd K. G., Worms P., Zivkovic B., Scatton B., Bartholini G. Interaction of GABA mimetics with nigro-striatal dopamine neurons. Brain Res. Bull. 5(Suppl. 2):1980;439-445.
30. Lloyd K. G., Arbilla S., Beaumon K., Briley M., Demontis G. M., Scatton B., Langer S. Z., Bartholini G. Gamma-aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. J. Pharmacol. Exp. Ther. 220:1982;672-677.
31. Löscher W., Hörstermann D. Differential effects of vigabatrin, γ-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;270-278.
32. Maccari S., Piazza P. V., Deminére J. M., Lemaire V., Mormède P., Simon H., Angelucci L., Le Moal M. Life events decrease of corticosteroid type I receptors is associated with reduced vulnerability to amphetamine self-administration. Brain Res. 547:1991;7-12.
33. Maier S. F., Ryan S. M., Barksdale C. M., Kalin N. H. Stressor controllability and the pituitary-adrenal system. Behav. Neurosci. 100:1986;669-674.
34. B receptors and the effects of baclofen in the mammalian central nervous system. Prog. Neurobiol. 46:1995;423-462.
35. Misslin R., Cigrang M. Does neophobial necessarily imply fear or anxiety. Behav. Proc. 12:1986;45-50.
36. Misslin R., Ropartz. P Effects of metamphetamine on novelty-seeking behavior by mice. Psychopharmacology (Berlin). 75:1981;39-43.
37. B receptors Eur. J. Pharmacol. 187:1990;27-38.
38. Olsen R. W., Ban M., Miller T., Johnson G. A. R. Chemical instability of the GABA antagonist bicuculline under physiological conditions. Brain Res. 98:1975;383-387.
39. Paredes R. G., Ågmo A. GABA and behavior. The role of receptor subtypes Neurosci. Biobehav. Rev. 16:1992;145-170.
40. B antagonist CGP 35348 inhibits the effects of baclofen on sexual behavior and motor coordination. Brain Res. Bull. 36:1995;495-497.
41. Pellow S., Chopin P., File S. E., Briley M. Validation of open:closed arms entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
42. Petersen E. N., Jensen L. H. Proconflict affect of benzodiazepine inverse agonists and other inhibitors of GABA function. Eur. J. Pharmacol. 103:1984;91-97.
43. Polenzani L., Woodward R. M., Miledi R. Expression of mammalian gamma-aminobutyric acid receptors with distinct pharmacology in Xenopus oocytes. Proc. Natl. Acad. Sci. USA. 88:1991;438-4322.
44. Robbins T., Iversen S. D. A dissociation of the effects of d-amphetamine on locomotor activity and exploration in rats. Psychopharmacologia. 28:1973;155-164.
45. Roberts D. C. S., Andrews M. M., Vickers G. J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology. 15:1996;417-423.
46. Rolinski Z., Scheel-Krüger J. The effect of dopamine and noradrenaline antagonists on amphetamine induced locomotor activity in mice and rats. Acta Pharmacol. Toxicol. 33:1973;385-399.
47. Rushton R., Steinberg H. Combined effects of chlordiazepoxide and dexamphetamine on activity of rats in an unfamiliar environment. Nature. 211:1966;1312-1313.
48. Sandoval M. R. L., Palermo-Neto J. Effect of manipulation of the GABA system on dopamine-related behaviors. Braz. J. Med. Biol. Res. 28:1995;88-99.
49. Sansone M. Influence of benzodiazepine tranquilizers on amphetamine-induced locomotor stimulation in mice. Psychopharmacology (Berlin). 71:1980;63-65.
50. Sansone M., Renzi P., Vetulani J. Facilitation of stimulatory effect of chlordiazepoxide-amphetamine combination by subacute administration of chlordiazepoxide in mice. Psychopharmacology (Berlin). 89:1986;52-54.
51. B receptor agonists and antagonists. Brain Res. 630:1993;28-31.
52. Santiago M., Machado A., Cano J. In vivo release of dopamine from rat striatum, substantia nigra and prefrontal cortex. Differential modulation by baclofen Br. J. Pharmacol. 109:1993;814-818.
53. Scatton B., Zivkovic B., Dedek J., Lloyd K. G., Constrantinidis J., Tissot R., Bartholini G. γ-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J. Pharmacol. Exp. Ther. 220:1982;678-688.
54. Scheel-Krüger J., Christensen A. V., Arnt J. Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drugs. A complex GABA-dopamine interaction Life Sci. 22:1978;75-84.
55. Shephard R. A. Valproate enhances fluid consumption suppressed by shock or neophobia, but not by partial satiation or d-amphetamine, in rats. Life Sci. 43:1988;897-904.
56. Simon P., Panissaud C., Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. Psychopharmacology (Berlin). 114:1994;597-600.
57. Sivilotti L., Nistri A. Pharmacology of a novel effect of gamma-aminobutyric acid on the frog tectum in vitro. Eur. J. Pharmacol. 164:1989;205-212.
58. Waldmeier P. C., Maitre L. Effects of baclofen on dopamine metabolism and interaction with neuroleptic effects. Eur. J. Pharmacol. 47:1978;191-200.
59. B and NMDA receptor agonists on medial forebrain bundle self-stimulation. Behav. Brain Res. 70:1995;31-36.
60. Wise R. A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19:1996;319-340.
61. B receptor agonists and antagonists. Mol. Pharmacol. 43:1993;609-625.
62. Worms P., Deporteere H., Durand A., Morselli P. L., Lloyd K. G., Bartholini G. Gamma-aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profile of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J. Pharmacol. Exp. Ther. 220:1982;660-671.
63. Yoshida M., Yokoo H., Tanaka T., Emoto H., Tanaka M. Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. Brain Res. 636:1994;111-114.
64. Zarevics P., Setler P. E. Effects of GABAergic drugs on brain stimulation reward as assessed by a 'threshold' method. Brain Res. 215:1981;201-209.